[1] Mills KT, Stefanescu A, He J, et al. The global epidemiology of hypertension. Nat Rev Nephrol 2020; 16: 223−237. doi: 10.1038/s41581-019-0244-2 [2] Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016; 134: 441−450. doi: 10.1161/CIRCULATIONAHA.115.018912 [3] Acelajado MC, Hughes ZH, Oparil S, et al. Treatment of resistant and refractory hypertension. Circ Res 2019; 124: 1061−1070. doi: 10.1161/CIRCRESAHA.118.312156 [4] Li L, Hu Z, Xiong Y, et al. Device-based sympathetic nerve regulation for cardiovascular diseases. Front Cardiovasc Med 2021; 8: 803984. doi: 10.3389/fcvm.2021.803984 [5] Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; 391: 2346−2355. doi: 10.1016/S0140-6736(18)30951-6 [6] Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020; 395: 1444−1451. doi: 10.1016/S0140-6736(20)30554-7 [7] Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021; 397: 2476−2486. doi: 10.1016/S0140-6736(21)00788-1 [8] Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393−1401. doi: 10.1056/NEJMoa1402670 [9] Mahfoud F, Schmieder RE, Azizi M, et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J 2017; 38: 3272−3281. doi: 10.1093/eurheartj/ehx215 [10] Mahfoud F, Mancia G, Schmieder R, et al. Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol 2020; 75: 2879−2888. doi: 10.1016/j.jacc.2020.04.036 [11] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36: 1953−2041. doi: 10.1097/HJH.0000000000001940 [12] Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003; 73: 712−716. doi: 10.1046/j.1445-2197.2003.02748.x [13] Follmann D, Elliott P, Suh I, et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769−773. doi: 10.1016/0895-4356(92)90054-Q [14] Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019; 10: ED000142. doi: 10.1002/14651858.ED000142 [15] Ewen S, Ukena C, Linz D, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension 2015; 65: 193−199. doi: 10.1161/HYPERTENSIONAHA.114.04336 [16] Fengler K, Rommel KP, Hoellriegel R, et al. Pulse wave velocity predicts response to renal denervation in isolated systolic hypertension. J Am Heart Assoc 2017; 6: e005879. doi: 10.1161/JAHA.117.005879 [17] Mahfoud F, Bakris G, Bhatt DL, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY registry. Eur Heart J 2017; 38: 93−100. doi: 10.1093/eurheartj/ehw325 [18] Chernin G, Szwarcfiter I, Scheinert D, et al. First-in-man experience with a novel catheter-based renal denervation system of ultrasonic ablation in patients with resistant hypertension. J Vasc Interv Radiol 2018; 29: 1158−1166. doi: 10.1016/j.jvir.2018.03.022 [19] Fengler K, Rommel KP, Lapusca R, et al. Renal denervation in isolated systolic hypertension using different catheter techniques and technologies. Hypertension 2019; 74: 341−348. doi: 10.1161/HYPERTENSIONAHA.119.13019 [20] Mahfoud F, Townsend RR, Kandzari DE, et al. Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol 2021; 77: 2909−2919. doi: 10.1016/j.jacc.2021.04.044 [21] Li L, Xiong Y, Hu Z, et al. Effect of renal denervation for the management of heart rate in patients with hypertension: a systematic review and meta-analysis. Front Cardiovasc Med 2022; 8: 810321. doi: 10.3389/fcvm.2021.810321 [22] Tsai TY, Cheng HM, Chuang SY, et al. Isolated systolic hypertension in Asia. J Clin Hypertens (Greenwich) 2021; 23: 467−474. doi: 10.1111/jch.14111 [23] Flint AC, Conell C, Ren X, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med 2019; 381: 243−251. doi: 10.1056/NEJMoa1803180 [24] Bavishi C, Goel S, Messerli FH, et al. Isolated systolic hypertension: an update after SPRINT. Am J Med 2016; 129: 1251−1258. doi: 10.1016/j.amjmed.2016.08.032 [25] Brandt MC, Reda S, Mahfoud F, et al. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol 2012; 60: 1956−1965. doi: 10.1016/j.jacc.2012.08.959 [26] Schmieder RE, Mahfoud F, Mancia G, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens 2021; 39: 1733−1741. doi: 10.1097/HJH.0000000000002933 [27] Mulder J, Hökfelt T, Knuepfer MM, et al. Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol 2013; 304: R675−R682. doi: 10.1152/ajpregu.00599.2012 [28] Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022; 399: 1401−1410. doi: 10.1016/S0140-6736(22)00455-X [29] Sakakura K, Roth A, Ladich E, et al. Controlled circumferential renal sympathetic denervation with preservation of the renal arterial wall using intraluminal ultrasound: a next-generation approach for treating sympathetic overactivity. EuroIntervention 2015; 10: 1230−1238. doi: 10.4244/EIJY14M10_14 [30] Al Raisi SI, Pouliopoulos J, Barry MT, et al. Evaluation of lesion and thermodynamic characteristics of Symplicity and EnligHTN renal denervation systems in a phantom renal artery model. EuroIntervention 2014; 10: 277−284. doi: 10.4244/EIJV10I2A46 [31] Fengler K, Rommel KP, Blazek S, et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation 2019; 139: 590−600. doi: 10.1161/CIRCULATIONAHA.118.037654 [32] Cheng Y, Liu H, Tian Z, et al. Comparison of ablation characteristics of three different radiofrequency applicators in renal sympathetic denervation. Int J Hyperthermia 2021; 38: 1251−1262. doi: 10.1080/02656736.2021.1963849 [33] García-Touchard A, Maranillo E, Mompeo B, et al. Microdissection of the human renal nervous system: implications for performing renal denervation procedures. Hypertension 2020; 76: 1240−1246. doi: 10.1161/HYPERTENSIONAHA.120.15106 [34] Fengler K, Ewen S, Höllriegel R, et al. Blood pressure response to main renal artery and combined main renal artery plus branch renal denervation in patients with resistant hypertension. J Am Heart Assoc 2017; 6: e006196. doi: 10.1161/JAHA.117.006196